MORETTI, ERICA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 758
EU - Europa 178
AS - Asia 84
Totale 1.020
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 753
IE - Irlanda 71
CN - Cina 44
IT - Italia 35
SE - Svezia 28
FI - Finlandia 20
HK - Hong Kong 18
SG - Singapore 17
RU - Federazione Russa 9
GB - Regno Unito 6
CA - Canada 5
DE - Germania 4
JO - Giordania 3
IN - India 2
UA - Ucraina 2
CZ - Repubblica Ceca 1
MK - Macedonia 1
NL - Olanda 1
Totale 1.020
Salva come PNG Salva come JPEG
Città #
Fairfield 130
Cambridge 74
Ashburn 71
Dublin 71
Seattle 69
Woodbridge 67
Houston 51
Chandler 46
Wilmington 45
Beijing 40
Princeton 21
Boston 20
Singapore 16
Ann Arbor 14
San Diego 11
Florence 9
Altamura 8
Boardman 8
Lawrence 8
Norwalk 6
Hillsboro 5
Medford 5
Toronto 5
Andover 4
Moscow 4
New York 4
Shanghai 4
Bremen 3
London 3
San Marzano sul Sarno 3
Hong Kong 2
Los Angeles 2
Lucera 2
Pune 2
Anguillara Sabazia 1
Busto Arsizio 1
Dearborn 1
Falls Church 1
Grevenbroich 1
Loucany 1
Pignone 1
Skopje 1
Totale 841
Salva come PNG Salva come JPEG
Nome #
Targeting triple negative breast cancer: is p53 the answer? 77
Adjuvant chemotherapy: which patient? What regimen? 75
The continued evidence from overviews: What is the clinical utility? 67
Targeting triple negative breast cancer: is p53 the answer? 66
TOP2A protein by quantitative immunofluorescence as a predictor of response to epirubicin in the neoadjuvant treatment of breast cancer. 66
Management of Aromatase Inhibitor-Resistant Disease with Estrogen, Selective Estrogen Receptor Down-Regulators, and Other Agents 62
Predictive molecular markers of anthracycline effectiveness in early breast cancer 57
Re-searching anthracycline therapy 57
Taxanes in the elderly: Can we gain as much and be less toxic? 57
Fulvestrant in the management of postmenopausal women with advanced, endocrine-responsive breast cancer 55
Predicting anthracycline benefit: have we made any progress? 52
Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients. 51
Adjuvant systemic treatment for individual patients with triple negative breast cancer 50
Anthracyclines: the first generation of cytotoxic targeted agents? A possible dream 48
Re: Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy 37
Patients with triple negative breast cancer. 27
The role of topoisomerase II alpha and HER-2 in predicting sensitivity to anthracyclines in breast cancer patients 24
Risk assessment of disease recurrence in early breast cancer: A serum metabolomic study focused on elderly patients 23
Can we use anthracyclines as targeted agents?. 23
Topoisomerase 2 alpha (TOP2A) protein by automated quantitative analysis (AQUA) as a marker predicting sensitivity to single-agent epirubicin (E) in the neoadjuvant treatment of endocrine-resistant breast cancer (H-BC) 22
Triple negative breast cancer: a heterogeneous subgroup defined by what it is not 21
Plasma Thymidine Kinase Activity as a Biomarker in Patients with Luminal Metastatic Breast Cancer Treated with Palbociclib within the TREnd Trial 6
Totale 1.023
Salva come PNG Salva come JPEG
Categoria #
all - tutte 3.273
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.273
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020298 26 12 5 21 34 37 33 33 32 26 32 7
2020/202188 7 11 3 2 7 10 2 10 12 9 11 4
2021/2022108 9 10 0 9 4 7 4 7 7 4 1 46
2022/2023227 38 16 3 12 22 43 40 14 19 4 15 1
2023/202497 3 14 24 6 5 12 8 11 4 4 3 3
2024/202513 13 0 0 0 0 0 0 0 0 0 0 0
Totale 1.023